Transplantation of Human Undifferentiated Embryonic Stem Cells into A Myocardial Infarction Rat Model by Xie, Chang-Qing et al.
STEM CELLS AND DEVELOPMENT 16:25–29 (2007)
© Mary Ann Liebert, Inc.
DOI: 10.1089/scd.2006.110206
Original Research Report
Transplantation of Human Undifferentiated Embryonic Stem
Cells into a Myocardial Infarction Rat Model
CHANG-QING XIE,1,2 JIFENG ZHANG,1,2 YAN XIAO,1 LI ZHANG,1,3 YONGSHAN MOU,1,4
XIAOWEI LIU,1 MUKAILA AKINBAMI,1 TAIXING CUI,1,2 and YUQING E. CHEN1,2
ABSTRACT
Human embryonic stem (hES) cells hold great therapeutic potential for cell transplantation. To date,
it remains uncertain whether undifferentiated hES cells can differentiate into cardiac lineage in vivo
during myocardial infarction. Here we provide the first report that undifferentiated hES cells can
survive in rat hearts during myocardial infarction without the formation of teratoma using undif-
ferentiated green fluorescent protein (GFP)-transgenic hES cells. Using a laser-capture microscope
to dissect the GFP-positive cell area from the hES-injected hearts, we documented the expression
of human cardiac-specific genes, including GATA-4, Nkx-2.5, and cardiac troponin I. Taken to-
gether, our results demonstrate that undifferentiated hES cells can be driven to the cardiac lineage
under the local injured environment in the heart, which may provide a potential method for re-
generating de novo myocardium to treat myocardial infarction.
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INTRODUCTION
MYOCARDIAL INFARCTION (MI) is the leading causeof congestive heart failure and death in developed
countries. The current pharmacotherapy and various in-
terventional and surgical therapeutic methods for MI are
limited in preventing deterioration of heart function, par-
tially due to their inability to repair or replace damaged
myocardium and regenerate new myocardium. Because
functional restoration of the damaged heart presents a for-
midable challenge, it is imperative to develop new strate-
gies for patients with MI (1,2).
The use of cellular therapy offers a promising approach
for MI treatment. Different types of regenerating cells are
currently being employed to determine their capacity for
the treatment of MI in the clinic (3). Recent randomized
controlled clinical studies have been conducted to ana-
lyze the efficacy of bone marrow-derived stem cell trans-
plantation therapy after acute MI. Although some of these
studies have showed significant improvement in cardiac
function, others showed ambiguous results (4,5). Indeed,
there is little evidence to show that bone marrow-derived
stem cells are able to regenerate cardiomyocytes (4,5).
Although cardiomyocytes derived from human embry-
onic stem (hES) cells have been documented to integrate
efficiently into of the hearts of host animals (3,6,7,8), the
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possibility of undifferentiated hES cells as transplanted cell
types for MI have not been examined. In the present study,
using undifferentiated green fluorescent protein (GFP)-
transgenic hES cells, we documented for the first time that
undifferentiated hES cells can survive in the rat hearts dur-
ing MI with human cardiac-specific gene expression.
MATERIALS AND METHODS
GFP-transgenic hES cell culture
GFP-transgenic hES cells were derived from WiCell
H1 cells (passage 33) transfected with lentiviral vectors
encoding enhanced green fluorescent protein (EGFP).
The undifferentiation and pluripotency of these derived
cells had been reported (9). The GFP-transgenic hES cells
were expanded routinely on Matrigel with conditioned
medium as described (10).
MI model and cell transplantation
MI in male Sprague-Dawley rats at 6 weeks of age was
induced by ligation of the left anterior descending coro-
nary artery, as previously described (11). Infarcted ani-
mals were grouped randomly into sham- and GFP-trans-
genic hES cell treatment. Successful occlusion was
recognized by pallor of the anterior left ventricular free
wall. Once the infarcted area stopped to increase (around
30 min), the culture medium (20 l) without cells (sham)
or 5  105 GFP-transgenic hES cells in 20 l of medium
were injected through a 25-gauge needle at the left ven-
tricular base along the border of the left ventricular in-
farcted areas. No antiimmunological rejection drugs were
given to rats. All animal experimental protocols were ap-
proved by the Animal Use and Care Committee of the
Morehouse School of Medicine.
Laser-capture microdissection
GFP-positive areas in hearts of hES cell-injected group
were isolated by the laser-capture microdissection (LCM)
system (Leica Microsystems, Deerfield, IL) using a mi-
nor modification of a method described previously (12).
Briefly, sections (10 m thick) were cut using a cryostat
(CM 1850, Leica Microsystems) and thaw-mounted onto
uncharged glass slides. LCM was performed by cutting
selected GFP-positive areas into HS-CapSure non-con-
tact LCM film (Leica). Microdissected cell clumps were
immediately processed for RNA isolation using the
RNeasy micro kit (Qiagen, Valencia, CA) as described
by the manufacturer.
Reverse transcription PCR
The cDNA was synthesized using Superscript III first-
strand synthesis system (Invitrogen, Carlsbad, CA). The
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TABLE 1. PRIMER SEQUENCES
Gene Sequence Product size (bp)
Oct-4 F: 5-gaaggtattcagccaaacga-3 216
R: 5-aaattctccagggttgcctct-3
Nanog F: 5-actccatgaacatgcaacct-3 166
R: 5-actggataggcatcatggaa-3
GATA-4 F: 5-tcctggaaagaagacgactg-3 219
R: 5-gattttggagtgaggggtct-3
Nkx2.5 F: 5-ggattttgcattcactcctg-3 196
R: 5-agctcagtcccagttccaa-3
cTnI F: 5-actgaccctccaaacgcccc-3 256
R: 5-cctctcgctccagctcttgc-3
18sRNA F: 5-ggaagggcaccaccaggagt-3 317
R: 5-tgcagccccggacatctaag-3
F, Forward; R, reverse.
FIG. 1. Transplantation of GFP-transgenic hES cells into the myocardial infarcted heart. (A) Morphology of GFP-transgenic
hES cultured on Matrigel-coated plate, viewed by phase-contrast (left) and fluorescence (right) microscopy, respectively. (B) In-
farction of rat hearts induced by ligation of the left anterior descending coronary artery. The arrowhead indicates the site of hu-
man GFP-ES cell injection near the infarcted area (circled). (C) Hematoxylin & Eosin staining showing the infarction of rat
hearts. Bar, 100 m. (D) Reprehensive image showing the robust fluorescence in the injected area 2 months after GFP-hES cell
injection. Bar, 100 m.
FIG. 2. Human cardiac-specific gene expression in the rat MI
hearts injected with GFP-hES cells. (A) Schematic representa-
tion of the membrane mounted specimen in LCM. The left and
right panels represent before and after LCM, respectively. (B)
Representative fluorescent images showing before (left) and af-
ter (right) if LCM, respectively. Bar, 100 m. (C) Human car-
diac-specific genes are expressed in the GFP-positive areas dis-
sected from rat MI hearts injected with GFP-hES cells by
RT-RCR. Line 1, Human heart RNA purchased from Clontech
(Cat#: 636532); line 2, undifferentiated GFP-transgenic hES
cells; lines 3–5, sham-operated control rat hearts; lines 6–8,
three MI rat hearts injected with undifferentiated GFP-trans-
genic hES cells.
FIG. 1.
levels of transcripts were determined by PCR. All primers
were designed to be specific to human cardiac genes. The
PCR primers used are described in Table 1.
RESULTS AND DISCUSSION
To date, regenerative medicine offers a promising ap-
proach for the treatment of MI. As the first step in ad-
dressing whether undifferentiated hES cells are a poten-
tially therapeutical resource for the future MI treatment,
we used hES cells with sustained GFP expression (9) to
study the consequence of hES cell transplantation (Fig.
1A) in a rat model of MI. The GFP-transgenic hES cells
were injected into the left ventricular base of the heart
(Fig. 1B). As expected, fibrosis in the infarcted area of
MI sections was observed after the MI (Fig. 1C). To eval-
uate the survival of hES cells, sections of the infarcted
area were examined for GFP levels. Interestingly, there
was robust green fluorescence in the area of rat hearts in-
jected with hES cells (Fig. 1D), suggesting that hES cells
can survive in the rat heart at least 2 months after MI. In
addition, there was no teratoma formation observed in all
tissues examined, including the heart, liver, and kidney
(data not shown). Failure of teratoma formation may be
due to the maintenance of proper signals provided by the
injured environment that drives undifferentiated hES
cells to directed differentiation without uncontrolled
growth (13,14).
Among 11 hES cell transplantation rats, 5 had GFP
fluorescence in the injected area of MI rat hearts. To de-
termine whether cardiomyocytes were differentiated
from the injected hES cells in the rat MI hearts, we dis-
sected GFP-positive cell areas using a laser capture mi-
crodissection system (Fig. 2A,B). Intriguingly, there were
human cardiac-specific gene including GATA-4,
NKX2.5, and cardiac troponin I (cTnI) expressed in the
GFP-positive samples from rat MI hearts injected with
hES cells (lanes 6–8 in Fig. 2C). As expected, the sham
control rat hearts did not express any human cardiac-spe-
cific gene (lanes 3–5 in Fig. 2C). In addition, there was
no expression of undifferentiated hES cell-specific mark-
ers (e.g., Oct-4 or NANOG) detected in the transplanta-
tion group, suggesting that hES cells injected into the MI
rat heart underwent differentiation.
Taken together, our results demonstrate for the first
time that undifferentiated hES cells can be differentiated
to the cardiac lineage under the local environmental sig-
nals in the heart. The signaling processes involved in di-
recting ES cell differentiation to cardiomyocytes in the
heart are only beginning to be studied actively. The con-
tinuation of these studies may provide a supplemental
method for regenerating de novo cardiomyocytes to 
treat MI.
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